2013 ACC/AHA cholesterol guideline for reducing cardiovascular risk: what is so controversial?

Curr Atheroscler Rep. 2014 Jun;16(6):413. doi: 10.1007/s11883-014-0413-5.


In November 2013, the American College of Cardiology and American Heart Association (ACC/AHA) released a clinical practice guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease (ASCVD) risk in adults. The guideline recommendations were developed from a rigorous systematic review of randomized, controlled trials (RCTs) and meta-analyses of RCTs that evaluated ASCVD outcomes. Major recommendations address a healthy lifestyle, identification of groups of patients most likely to experience a net benefit form statin therapy, appropriate intensity of statin therapy to reduce ASCVD, safety, decision-making in primary prevention, monitoring therapy, and appropriate use of nonstatin therapy. Areas of controversy are discussed.

Publication types

  • Review
  • Systematic Review

MeSH terms

  • Cardiovascular Diseases / diagnosis
  • Cardiovascular Diseases / drug therapy*
  • Cardiovascular Diseases / prevention & control
  • Cholesterol / blood*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Life Style
  • Practice Guidelines as Topic*
  • Risk Factors
  • United States


  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Cholesterol